Stemline – About the Company
SL-401 demonstrated single agent activity in multiple indications, including durable CRs in relapsed/refractory AML and relapsed/refractory BPDCN. In addition, SL-401 was well-tolerated and not toxic to the bone marrow. SL-401 is being advanced into pivotal Phase 2b programs in relapsed or refractory BPDCN and third-line AML.
Stemline’s second clinical candidate SL-701 has demonstrated single agent activity including durable CRs and PRs in adult patients with refractory/recurrent glioblastoma and pediatric patients with malignant glioma. This product is now ready to enter later stage trials in pediatric and adult patients with advanced brain cancer.